Armbruster, Shannon D., Rebecca Previs, Pamela T. Soliman, Shannon N. Westin, Bryan Fellman, Anuja Jhingran, and Nicole D. Fleming. “Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience..” Gynecol Oncol 154, no. 2 (August 2019): 328–32. https://doi.org/10.1016/j.ygyno.2019.06.001.
Rebecca A Previs, MD
Education and Training
- M.D., University of Virginia School of Medicine, 2009
Research interests include early phase clinical trials, novel therapeutics, the microenvironment, and personalized medicine. I am working on translating what we learn at the laboratory bench into better therapies for our patients. I am interested in gaining a better understanding of the immune microenvironment to determine how cancer cells evade discovery by our own immune systems.
Selected Grants and Awards
- Novel see and treat strategies for cervical cancer prevention in low-resource settings
- Immune modulation of CaMKK2 in the ovarian tumor microenvironment
- Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer
- Evaluation of homologous recombination deficiency in uterine serous cancer
- Janet Burros Ovarian Cancer Repository
Berger, Miles, Deborah Oyeyemi, Mobolaji O. Olurinde, Heather E. Whitson, Kent J. Weinhold, Marty G. Woldorff, Lewis A. Lipsitz, et al. “The INTUIT Study: Investigating Neuroinflammation Underlying Postoperative Cognitive Dysfunction..” J Am Geriatr Soc 67, no. 4 (April 2019): 794–98. https://doi.org/10.1111/jgs.15770.
Davidson, Brittany A., Gloria Broadwater, Aleia Crim, Robert Boccacio, Kristin Bixel, Floor Backes, Rebecca A. Previs, et al. “Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy..” Gynecol Oncol 152, no. 3 (March 2019): 554–59. https://doi.org/10.1016/j.ygyno.2018.12.011.
Kurnit, Katherine C., Rebecca A. Previs, Pamela T. Soliman, Shannon N. Westin, Ann H. Klopp, Bryan M. Fellman, Karen H. Lu, Lois M. Ramondetta, and Nicole D. Fleming. “Prognostic factors impacting survival in early stage uterine carcinosarcoma..” Gynecol Oncol 152, no. 1 (January 2019): 31–37. https://doi.org/10.1016/j.ygyno.2018.10.034.
Allen, Julie K., Guillermo N. Armaiz-Pena, Archana S. Nagaraja, Nouara C. Sadaoui, Tatiana Ortiz, Robert Dood, Merve Ozcan, et al. “Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction..” Cancer Res 78, no. 12 (June 15, 2018): 3233–42. https://doi.org/10.1158/0008-5472.CAN-16-1701.
Huang, Yan, Wei Hu, Jie Huang, Fangrong Shen, Yunjie Sun, Cristina Ivan, Sunila Pradeep, et al. “Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer..” Mol Cancer Ther 17, no. 2 (February 2018): 464–73. https://doi.org/10.1158/1535-7163.MCT-17-0006.
Dalton, Heather J., Sunila Pradeep, Michael McGuire, Yared Hailemichael, Shaolin Ma, Yasmin Lyons, Guillermo N. Armaiz-Pena, et al. “Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression..” Clin Cancer Res 23, no. 22 (November 15, 2017): 7034–46. https://doi.org/10.1158/1078-0432.CCR-17-0647.
Previs, Rebecca A., Guillermo N. Armaiz-Pena, Cristina Ivan, Heather J. Dalton, Rajesha Rupaimoole, Jean M. Hansen, Yasmin Lyons, et al. “Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies..” J Natl Cancer Inst 109, no. 7 (July 1, 2017). https://doi.org/10.1093/jnci/djw296.